Saint Louis University proposes to evaluate acellular Bordetella pertussis vaccines, conjugated Haemophilus influenza type b and other bacterial vaccines, live attenuated influenza A and B virus vaccines, live attenuated parainfluenza virus vaccines, rotavirus vaccines and other vaccines such as herpes vaccines and hepatitis A vaccines as they become available. Sample protocols have been previously submitted and these are designed to illustrate our approach to testing vaccines of different types including vaccinia vector vaccines. The protocols summarize our plans to develop independent and collaborative protocols and work closely with other vaccine centers, the NIAID, and industry in evaluating vaccines for use in the general population. We propose to conduct clinical evaluation of investigational vaccines, and in addition we propose to develop new candidate vaccines such as parainfluenza virus vaccines and evaluation of antiviral compounds and other measures of controlling infections. We propose to study the epidemiology of viral infections including the subtype epidemiology of respiratory syncytial virus; vaccine studies in the elderly are proposed. This vaccine center will retain its major focus on evaluating vaccines in infants and children; however, we do have the experience and populations to evaluate vaccines in young adults and the elderly including studies in an isolation unit.

Project Start
1989-10-08
Project End
1994-10-07
Budget Start
1991-10-11
Budget End
1992-10-07
Support Year
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Saint Louis University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63103
Rennels, Margaret B; Deloria, Maria A; Pichichero, Michael E et al. (2002) Lack of consistent relationship between quantity of aluminum in diphtheria-tetanus-acellular pertussis vaccines and rates of extensive swelling reactions. Vaccine 20 Suppl 3:S44-7
Pichichero, M E; Anderson, E L; Rennels, M B et al. (2001) Fifth vaccination with dipthteria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatr Infect Dis J 20:427-33
Pichichero, M E; Edwards, K M; Anderson, E L et al. (2000) Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics 105:e11
Weiss, A A; Mobberley, P S; Fernandez, R C et al. (1999) Characterization of human bactericidal antibodies to Bordetella pertussis. Infect Immun 67:1424-31
Keitel, W A; Muenz, L R; Decker, M D et al. (1999) A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J Infect Dis 180:397-403
Powers, D C (1997) Summary of a clinical trial with liposome-adjuvanted influenza A virus vaccine in elderly adults. Mech Ageing Dev 93:179-88
Ray, R; Galinski, M S; Heminway, B R et al. (1996) Temperature-sensitive phenotype of the human parainfluenza virus type 3 candidate vaccine strain (cp45) correlates with a defect in the L gene. J Virol 70:580-4
Anderson, E L; Decker, M D; Englund, J A et al. (1995) Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants. JAMA 273:849-53
Ray, R; Meyer, K; Newman, F K et al. (1995) Characterization of a live, attenuated human parainfluenza type 3 virus candidate vaccine strain. J Virol 69:1959-63
Karron, R A; Froehlich, J L; Bobo, L et al. (1994) Rapid detection of parainfluenza virus type 3 RNA in respiratory specimens: use of reverse transcription-PCR-enzyme immunoassay. J Clin Microbiol 32:484-8

Showing the most recent 10 out of 19 publications